InspireMD Announces Abstract Of 30-Day Results From The C-Guardians U.S. Investigational Device Exemption Clinical Trial Accepted for Presentation at VIVA23
Portfolio Pulse from Happy Mohamed
InspireMD, Inc. (NASDAQ:NSPR) has announced that an abstract detailing 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation at the VIVA23 conference. The trial is evaluating the safety and efficacy of the CGuard™ Carotid Stent System for the treatment of carotid artery stenosis. The company anticipates primary endpoint results from the study in H2 2024.
August 31, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
InspireMD's announcement of the acceptance of its abstract for presentation at VIVA23 could potentially boost investor confidence in the short term. However, the primary endpoint results from the study, expected in H2 2024, will be a more significant determinant of the stock's performance.
The announcement of the acceptance of the abstract for presentation at a prestigious conference like VIVA23 could be seen as a positive development, potentially boosting investor confidence in the short term. However, the actual impact on the stock's performance will largely depend on the primary endpoint results from the study, which are expected in H2 2024.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100